of patients with glioma. 2 Increasing evidence has indicated that the traditional classification of glioma provides very little insight into the biological behavior and molecular mechanisms that could be used as therapeutic targets. Therefore, the identification of new prognostic biomarkers is urgently needed to evaluate the malignancy and longterm outcome of glioma. 3, 4 Tribbles pseudokinase 2 (TRIB2) is a kinase-encoding gene of the tribbles family. TRIB2 was first identified to regulate mitosis and embryonic development in Drosophila. 5 Recent studies have indicated that TRIB2 functions as a crucial oncogene that regulates a wide range of cellular processes, including tumorigenesis, proliferation, invasion, and therapeutic resistance, in various subtypes of cancer, such as small cell lung cancer, liver cancers, colorectal cancer, and acute myeloid leukemia. [5] [6] [7] [8] Foulkes et al 9 demonstrated that TRIB2 expression is significantly increased in acute myeloid leukemia and promotes tumor proliferation by inactivating CCAATenhancer-binding protein α (C/EBPα). Moreover, Wnt/TCF signaling-dependent activation of TRIB2 stimulates the proliferation of liver cancer cells through a stabilization effect on yes-associated protein (YAP). 10 Hou et al 7 found that TRIB2 increases colorectal cancer tumor growth by decreasing the expression of p21, which functions as a tumor suppressor gene, indicating that TRIB2 could become a potential molecular target for colorectal cancer. These studies prompted the hypothesis that TRIB2 is a prognostic predictor for multiple types of malignant tumors. However, the functional role of TRIB2 and the underlying mechanism in glioma are poorly elucidated.
Mitogen-activated protein kinases (MAPKs) are essential regulators of evolutionarily conserved proteins that mediate various cellular physiologies. 11 The activation of MAPK networks includes 3 sequential phosphorylation strategies, from MAPK kinase kinases (MAP3Ks) to MAPK kinase (MAP2Ks) and MAPKs. 12 Mitogen-activated protein kinase kinase kinase 1 (MAP3K1), which is an important isoform for the first stimulation step of MAPKs, participates in regulating physiological and pathological processes, such as cell growth, cell migration, and apoptosis in gastric cancer, breast cancer, and nonsmall cell lung cancer cells. [13] [14] [15] Additionally, a mechanistic study has indicated that MAP3K1 promotes tumor progression via the specific phosphorylation of MAP2K4 and thus selectively phosphorylates and activates c-Jun N-terminal kinase (JNK). 16 MAP3K1 also activates JNK through the phosphorylation of MAP2K1/2 and MAP2K716. Despite these results, the function and mechanism of MAP3K in glioma are still not fully understood.
Increasing data have shown that kinase-dependent activation of tumorigenesis and therapeutic resistance is one of the major causes for GBM tumor recurrence, indicating that aberrant enhanced kinase activity could be a potential predictive biomarker for GBM. 4, [17] [18] [19] In this study, to further investigate prognostic biomarkers for glioma, kinome-wide screening was first performed with 3 GEO datasets (Mao et al, 20 2015, Tso et al, 21 2015, and Wang et al, 22 2017 ). TRIB2 and MAP3K1 were identified as genes that are correlated with the pathology and survival of glioma. Moreover, a combined increase in TRIB2 and MAP3K1 in glioma is associated with a poor prognosis and therapeutic resistance to TMZ and radiotherapy. These data suggest that TRIB2 and MAP3K1 could be used as novel therapeutic targets and prognostic biomarkers to evaluate the malignancy and long-term outcome of GBM.
| MATERIAL S AND ME THODS

| Patient and glioma samples
This study was approved by the patients and the Scientific Ethics Committee at the First Affiliated Hospital of Xi'an Jiaotong University (approval no. 2016-18). A total of 91 glioma samples and three nontumor tissue samples from epilepsy surgery were collected from patients who underwent surgical operations from 2008 to 2016. All necessary consent forms and documents were signed before the surgeries were performed. All samples were embedded in paraffin blocks, and 17 glioma samples and three nontumor tissues were immediately frozen and stored in liquid nitrogen for RNA purification.
| Gene expression analysis
Gene expression data were extracted from GEO datasets (Mao et al, 20 2015, Tso et al, 21 and Wang et al 22 ) . Hierarchical bi-clustering was performed to analyze the expression of the target genes by Cluster 3.0 software. Euclidean distance and average linkage were used as a similarity metric and clustering method, respectively.
Comparisons of the relative gene expression between the different groups are presented as fold changes.
| Gene set enrichment analysis (GSEA) and Kyoto encyclopedia of genes and genomes (KEGG) analysis
Gene expression profiles were derived from public databases, including the Cancer Genome Atlas (TCGA RNA sequencing) database and Gene Expression Omnibus (GEO, GSE16011). All data were preprocessed, including normalization and gene ID transformation, by R software, and these data were then ordered by the expression level of TRIB2 to divide all samples into two groups (TRIB2 high/low ) according to the median. The data were then or- 
| Quantitative RT-PCR (qRT-PCR)
Total RNA was prepared using an RNeasy mini kit according to the GAAGGTGAAGGTCGGAGTCA; and GAPDH reverse: TTGAGGTCAAT GAAGGGGTC. Relative quantification of cDNAs to GAPDH was conducted by the 2 −ΔΔCt method.
| Immunohistochemistry (IHC)
IHC was performed as previously described. 4, 23 Anti-TRIB2 and anti-MAP3K1 primary antibodies were purchased from Invitrogen (catalog no. MA5-24942). Horseradish peroxidase-conjugated goat anti-rabbit IgG (catalog no. ab97051) and goat anti-mouse IgG were obtained from Abcam (catalog no. ab205719) and used as secondary antibodies. All glioma samples used in this study were pathologically diagnosed, and recurrence was confirmed by computed tomography (CT) or magnetic resonance imaging (MRI). Nuclei were counterstained with hematoxylin.
| German immunohistochemistry score (GIS)
GIS was used to analyze the expression of TRIB2 and MAP3K1 as previously described. 22 The immunoreactivity score was calculated according to the following equation: immunoreactivity score = positive cell score × staining intensity score. The positive cell score was scored as follows: 0, negative; 1, <10% positive; 2, 11%-50% positive; 3, 51%-80% positive; and 4, >80% positive. The staining intensity score was scored as follows: 0, negative; 1, weakly positive; 2, moderately positive; and 3, strongly positive. An immunoreactivity ). D, Venn diagram indicated that TRIB2 was one of the four most differentially expressed kinase-encoding genes in these three databases score >5 was considered high expression, and ≤5 was defined as low expression.
| Receiver operating characteristic (ROC) analysis
For ROC analysis, all patients were divided into two groups based on the survival period. The expression of the genes of interest was calculated by GIS, and ROC analysis was performed with SPSS 22.0 software. The area under the curve (AUC) was used to evaluate the specificity and sensitivity of each cutoff. The statistical significance was compared with a Z test.
| Statistical analysis
All the results in this study are presented as the mean ± standard deviation. The number of replicates is mentioned in the related figure legends. Statistical differences between two groups were evaluated using 2-tailed t tests. Multiple groups were compared with one-way ANOVA followed by Dunnett's posttest. Kaplan-Meier survival analysis was compared by the log-rank test. All statistical analyses were performed with SPSS 22.0 or GraphPad Prism 6 software. A P-value less than 0.05 indicated statistical significance.
| RE SULTS
| Kinome-wide screening for prognostic biomarkers in glioma
To thoroughly explore the potential prognostic biomarkers for glioma, kinome-wide hierarchical bi-clustering was performed using Figure 1A -C, and Tables S1-S3). The genes that were more than 1.5-fold upregulated were selected from Tso et al 21 and Mao et al 20 Moreover, genes that were upregulated by 0.2-fold were extracted from the Wang et al 22 database. The overlapping genes from those three gene lists are summarized. Finally, we found that four kinase-encoding genes were significantly correlated with F I G U R E 2 MAP3K1 expression was correlated to TRIB2 in glioma. A, Spearman correlation analysis with TCGA showed that MAP3K1 was among the most correlated genes to TRIB2. B, TRIB2 mRNA showed a strong correlation to MAP3K1 mRNA in TCGA database (Spearman r = 0.81, P < 0.01, with paired t test) F I G U R E 3 TRIB2 and MAP3K1 were upregulated in gliomas. A-B, qRT-PCR showed elevated TRIB2 (A) and MAP3K1 (B) expression in 17 glioma samples compared with three nontumor tissues (*P < 0,05, with t test) characteristics of malignancy, including TMZ resistance, WHO grade, and radiotherapeutic resistance in GBM ( Figure 1D ). Since TRIB2 was identified as an essential oncogene in a variety of cancer types, we focused on TRIB2 for further characterization of glioma in this study.
| MAP3K1 expression was correlated with TRIB2 in glioma
Next, to investigate the candidate gene correlated with TRIB2, Spearman's correlation analysis was performed using TCGA RNA sequencing database. The results demonstrated that MAP3K1 is one of the most closely associated genes with TRIB2 in glioma ( Figure 2A,B) , indicating that MAP3K1 might be functionally regulated by TRIB2 and could be used as a potential combined biomarker for glioma. The detailed results are shown in Table S4 .
| TRIB2 and MAP3K1 were upregulated in gliomas
Seventeen glioma samples and three nontumor tissues were collected for RNA purification, and the expression levels of TRIB2 and MAP3K1 were evaluated by qRT-PCR. The results showed a significant increase in TRIB2 and MAP3K1 in the glioma samples compared with the nontumor samples ( Figure 3A,B) . Similarly, we assessed the expression of TRIB2 and MAP3K1 in glioma/GBM by analyzing the TCGA (RNA sequencing) database, and the results demonstrated that TRIB2 and MAP3K1 were markedly increased in glioma tissues, especially GBM tissues, compared with nontumor tissues (Figure 4A,B ).
| TRIB2 and MAP3K1 were significantly enriched in GBM
IHC was performed on 91 glioma samples to analyze the expression of TRIB2 and MAP3K1, and three brain tissues from epilepsy surgery were used as negative controls. The baseline information for the patients is shown in Table 1 . The IHC results showed that TRIB2 was predominantly expressed in the nucleus, and MAP3K1 was enriched in the cytoplasm and cytomembrane of glioma cells, F I G U R E 4 Gene expression analysis for TRIB2 and MAP3K1 in TCGA. A-B, Gene expression analysis with TCGA database showed that TRIB2 (A) and MAP3K1 (B) were highly expressed in GBM and low-grade glioma (LGG) when compared to nontumor tissue (*P < 0.05) No 68 while no significant staining was observed in the nontumor tissues ( Figure 5 ). In addition, the patients with glioma were divided into two groups according to the GIS of TRIB2 and MAP3K1 expression.
TA B L E 1 Baseline information for glioma patients involved in this study
The data indicated that TRIB2 and MAP3K1 were likely to be en- 
| The combined increase in TRIB2 and MAP3K1 suggested a poor prognosis of patients with glioma
As mentioned previously, correlated overexpression of TRIB2 and MAP3K1 could be associated with high-grade glioma. The survival of the patients was monitored until December 2016 and analyzed using the Kaplan-Meier method according to the expression of TRIB2 and MAP3K1. We found that patients with glioma and lower expression of TRIB2 or MAP3K1 exhibited prolonged overall survival compared with patients with glioma and higher TRIB2 or MAP3K1 expression ( Figure 7A,B) . Similar results were observed when the Rembrandt database was used to analyze 676 patient samples ( Figure 7C,D) . Figure 7E and Table 4 ). Additionally, ROC analysis was performed to evaluate the sensitivity and specificity of TRIB2 and MAP3K1 for the prediction of outcomes in patients with glioma.
The results indicated that the AUCs of TRIB2 and MAP3K1 were 0.822 (P < 0.01) and 0.855 (P < 0.01), respectively, and the AUC of the WHO classification of glioma was 0.789 (P = 0.000002), indicating that combined increases in TRIB2 and MAP3K1 are associated with significant sensitivity and specificity for the prediction of a poor prognosis in patients with glioma ( Figure 7F and Table 5 ).
Additionally, ROC analysis also showed an increased sensitivity and specificity for the combination of TRIB2 and MAP3K1 on the evaluation of survival compared with TRIB2 or MAP3K1 expression alone ( Figure 7G and Table 5 ). In addition, we grouped other potentially related prognostic factors for survival analysis using the log-rank test. The results indicated that multiple clinical characteristics, including age >50, high WHO grade, and presurgical epilepsy, were significant prognostic indicators for the survival of patients with glioma ( Figure S1A ,B,C, and Table 4 ). Although gene expression alterations associated with cancer survival were thoroughly investigated, more studies are required to fully understand the underlying biological mechanisms.
| Enriched TRIB2 and MAP3K1 were associated with TMZ resistance and radioresistance in glioma
As described previously, our kinome-wide screening results identified that TIRB2 was correlated with pathological malignancy and analysis also showed a strong correlation between the TRIB2 High /
MAP3K1High gene signature and multiple pathways associated with malignant cancers ( Figure 8F ). Interestingly, activation of MAPKK activity was also confirmed to be regulated by aberrant activation of TRIB2 ( Figure 8F ).
To clarify the potential predictive biomarkers of therapeutic resistance and pathological characteristics, the antitherapeutic characteristics of TRIB2 and MAP3K1 were analyzed. Survival data of 78 patients who received radiotherapy were extracted, and the Kaplan-Meier analysis showed that high expression of TRIB2 and MAP3K1 was conversely correlated with the poor survival of patients with glioma who were treated with radiotherapy ( Figure 9A) .
Similar results were observed for patients who received TMZ therapy ( Figure 9B ). Overall, these data suggest that enriched TRIB2 and MAP3K1, which could be used to predict the efficacy of routine adjuvant treatment for glioma, may indicate increased resistance to TMZ and radiotherapy.
| D ISCUSS I ON
Glioma accounts for 46% of all primary intracranial tumors in the central nervous system. 28 Increasing evidence has suggested that rapid acquired therapeutic resistance is the major cause of the failure of standard comprehensive treatments, leading to the recurrence and high mortality of glioma. 29, 30 Various molecular pathways have been shown to be responsible for the acquisition of therapeutic resistance in glioma. 26, [31] [32] [33] Therefore, it is essential to identify the mechanisms, especially prognostic biomarkers, underlying therapeutic resistance in glioma. In this study, we analyzed the transcriptome expression profiles of 3 published GEO databases related to pathological classification, radioresistance, and TMZ resistance and identified TRIB2
as the most correlated kinase-encoding gene that induces malignant phenotypes, such as higher pathological grade, radioresistance, and TMZ resistance in glioma. Additionally, MAP3K1 was identified as the most correlated gene to TRIB2. Next, combined overexpression of TRIB2 and MAP3K1 was identified in glioma and correlated with a poor prognosis of glioma with significant sensitivity and specificity. Moreover, enriched TRIB2 and MAP3K1 indicated resistance to TMZ and radiotherapy. Overall, our findings suggest that the combined increase in TRIB2 and MAP3K1 could be prognostic biomarkers and potential therapeutic targets for glioma.
Abnormally elevated TRIB2 was previously identified as the clinically relevant factor in various subtypes of human cancers. [5] [6] [7] [8] As MAP3K1 is a 196-kDa serine/threonine kinase that is activated by various stimuli and cell stresses, including growth factors, cytokines, and microtubule disruption. 35 Our present study showed elevated MAP3K1 expression in glioma, which is conversely associated with a poor prognosis and therapeutic resistance in glioma. Similar to our study, recent studies have shown that MAP3K1 is functionally required for multiple physiological processes, including cell growth, cell migration, and apoptosis, and is strongly correlated with poor outcomes in a wide range of malignant cancers. [13] [14] [15] Furthermore,
another study demonstrated that MAP3K1 promotes tumorigenesis in nonsmall cell lung cancer cells by regulating epithelial-mesenchymal transition through miR-145-5p-mediated JNK signaling pathway activation, suggesting the potential role of MAP3K1 as an important oncogene. 12, 15, 35 Increasing evidence has indicated that acquired resistance to chemotherapy and radiation leads to the rapid recurrence and poor prognosis of glioma in patients. 36 According to our results, MAP3K1
was the gene that was most correlated with TRIB2. Moreover, elevated coexpression of TRIB2 and MAP3K1 was significantly correlated with a poor prognosis and indicated therapeutic resistance in glioma. These novel findings indicated that TRIB2 and MAP3K1 could be potential predictors for evaluating the survival and efficacy of routine adjuvant treatments of glioma. In addition, multiple clinical characteristics, including age, pathological classification, and presurgical epilepsy, were significant prognostic indicators for the survival of patients with glioma. Interestingly, our survival analysis showed that patients with glioma and increased expression of TRIB2
and MAP3K1 exhibited worse responses to TMZ and radiotherapy.
The ROC analysis confirmed that the sensitivity and specificity of TRIB2/MAP3K1 expression were statistically significant, indicating that TRIB2/MAP3K1 expression should be investigated for evaluating the prognosis and therapeutic efficacy in patients with glioma.
These two molecules could be important biomarkers for traditional pathological classification in glioma. Overall, this study demonstrated the potential of TRIB2 and MAP3K1 as therapeutic targets in glioma.
| CON CLUS ION
TRIB2 and MAP3K1 could be used as novel therapeutic targets and prognostic biomarkers to evaluate the malignancy and long-term outcome of glioma.
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